logo
Businessman Morris Talansky, witness in Ehud Olmert trial, passes away at 92

Businessman Morris Talansky, witness in Ehud Olmert trial, passes away at 92

Yahoo02-06-2025

According to the verdict, Talansky transferred hundreds of thousands of dollars to former prime minister Olmert over several years.
Jewish-American businessman Morris Talansky passed away on Monday evening at the age of 92.
Talansky, who also goes by "Moshe," was known for serving as a key witness in the "Cash Envelopes" affair, in which former Prime Minister Ehud Olmert was convicted of receiving money illegally while serving as mayor of Jerusalem.
According to the verdict, Talansky transferred hundreds of thousands of dollars to Olmert over several years. At the trial, Olmert said in 2011 that he denied ever demanding cash bribes from Talansky, and added that the Jewish-American philanthropist's testimony at the trial claiming he lent Olmert tens of thousands of dollars was nothing but a made-up fantasy. Olmert responded by saying he received money from Talansky in the form of campaign donations.
Olmert's defense later said in September of that year that the donations from Talansky were legal, after prosecutors alleged that the former prime minister failed to report the donations to the State Comptroller.
The indictment said that Talansky gave Olmert the money as a personal loan, which the Israeli leader allegedly stashed away unreported to the tax authority.
He was laid to rest in a cemetery in Beit Shemesh, according to Ynet. He was an Orthodox Jew from Long Island, New York.
Both he and Olmert jointly founded the New Jerusalem Fund, a charity aimed at raising money for projects in Israel's capital.
Yaakov Lappin, Ron Friedman, and Joanna Paraszczuk contributed to this report.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Candace Owens Flips & Feels 'Embarrassed' She Ever Supported Trump, X Reacts
Candace Owens Flips & Feels 'Embarrassed' She Ever Supported Trump, X Reacts

Black America Web

timean hour ago

  • Black America Web

Candace Owens Flips & Feels 'Embarrassed' She Ever Supported Trump, X Reacts

Welp, it happened — Candace Owens has come to glory on the disastrous display of incompetence and non-leadership that is President Donald Trump. That's right, one of Trump's most loyal Sunken Place correspondents has had enough of her MAGA messiah, and now she's 'embarrassed' to have ever supported him. During a recent appearance on 'Piers Morgan Uncensored,' Owens revealed that she is no longer a Trump supporter, largely due to the president ordering B-2 bombers to strike three of Iran's nuclear facilities, butting the U.S.'s nose into the Israel-Iran conflict. (So, you know, not because Trump is a bigoted propagandist who appears to regularly pick and choose when the U.S. Constitution applies to his office. He had to be a warmonger on top of all that for Candace to finally give up on him.) 'He's been a chronic disappointment. And I feel embarrassed that I told people to go vote for him because this wasn't going to happen, and it is happening,' Owens said. The ex- Daily Wire commentator also suggested that Trump wasn't even pulling the strings when he ordered the bombing — which may or may not have actually destroyed Iran's nuclear weapon capabilities — and that the president is actually following the marching orders of Israeli Prime Minister Benjamin Netanyahu. 'This was not Trump's decision; it was Bibi Netanyahu's decision,' Owens said. 'And that is the reason that he did it. We're very aware that Israel is dictating our foreign policy, and we'd now like that to stop.' Anyway, Owens' about-face on Trump has resulted in mixed reactions on social media. Some are actually praising her for finally seeing the truth, while others are collectively side-eyeing her for trying to get back into the cookout. Then there are the MAGA supporters, who are turning on her faster than Trump turned on Fox News for accurately reporting his poll numbers. Check out some of the reactions below. Candace Owens Flips & Feels 'Embarrassed' She Ever Supported Trump, X Reacts was originally published on

Analog Devices' (NASDAQ:ADI) 16% CAGR outpaced the company's earnings growth over the same five-year period
Analog Devices' (NASDAQ:ADI) 16% CAGR outpaced the company's earnings growth over the same five-year period

Yahoo

timean hour ago

  • Yahoo

Analog Devices' (NASDAQ:ADI) 16% CAGR outpaced the company's earnings growth over the same five-year period

Passive investing in index funds can generate returns that roughly match the overall market. But the truth is, you can make significant gains if you buy good quality businesses at the right price. For example, the Analog Devices, Inc. (NASDAQ:ADI) share price is 95% higher than it was five years ago, which is more than the market average. Zooming in, the stock is up just 3.8% in the last year. On the back of a solid 7-day performance, let's check what role the company's fundamentals have played in driving long term shareholder returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). During five years of share price growth, Analog Devices achieved compound earnings per share (EPS) growth of 4.2% per year. This EPS growth is slower than the share price growth of 14% per year, over the same period. So it's fair to assume the market has a higher opinion of the business than it did five years ago. And that's hardly shocking given the track record of growth. This optimism is visible in its fairly high P/E ratio of 64.21. You can see how EPS has changed over time in the image below (click on the chart to see the exact values). Dive deeper into Analog Devices' key metrics by checking this interactive graph of Analog Devices's earnings, revenue and cash flow. It is important to consider the total shareholder return, as well as the share price return, for any given stock. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of Analog Devices, it has a TSR of 114% for the last 5 years. That exceeds its share price return that we previously mentioned. The dividends paid by the company have thusly boosted the total shareholder return. Analog Devices shareholders gained a total return of 5.6% during the year. Unfortunately this falls short of the market return. On the bright side, the longer term returns (running at about 16% a year, over half a decade) look better. It's quite possible the business continues to execute with prowess, even as the share price gains are slowing. It's always interesting to track share price performance over the longer term. But to understand Analog Devices better, we need to consider many other factors. Case in point: We've spotted 1 warning sign for Analog Devices you should be aware of. But note: Analog Devices may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Truist Reiterates Eli Lilly (LLY) Buy Rating on Orforglipron Diabetes Drug Data
Truist Reiterates Eli Lilly (LLY) Buy Rating on Orforglipron Diabetes Drug Data

Yahoo

timean hour ago

  • Yahoo

Truist Reiterates Eli Lilly (LLY) Buy Rating on Orforglipron Diabetes Drug Data

Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities reiterated its 'Buy' rating on Eli Lilly stock. The firm also maintained the price target of $1,038.00. Truist's move followed Eli Lilly's presentation at the American Diabetes Association (ADA) 85th Annual Meeting. Pixabay/Public Domain The rating pertains to Eli Lilly's oral diabetes drug, orforglipron (OFG), evaluated in the Phase 3 ACHIEVE-1 study for Type 2 diabetes treatment. The ACHIEVE-1 study results were presented at the ADA conference, showcasing orforglipron's efficacy and safety profile. The trial demonstrated statistically significant reductions in A1C (a long-term blood sugar metric) and body weight compared to placebo, with efficacy increasing at higher doses. Truist's analysis was informed by attending the orforglipron presentation, gathering feedback from KOLs at the ADA conference, and participating in Eli Lilly's investor event, where management provided clarity to alleviate safety concerns. The firm noted that longer-term data are required to further strengthen orforglipron's safety profile, particularly for chronic use in diabetes and potential obesity indications. Eli Lilly and Company (NYSE:LLY) is an American global biopharmaceutical company. The company discovers, develops, and markets prescription medicines for diabetes, obesity, cancer, immunological disorders, and neurological diseases. Its key products include Mounjaro, Zepbound, Trulicity, Verzenio, Taltz, and Jardiance. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store